Teva Industries, Ltd. has received approval for its AirDuo Digihaler (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder, a combination therapy digital inhaler that connects to a mobile app to provide information on inhaler use to people with asthma. The Digihaler is indicated for the treatment of asthma in patients aged 12 years and older. The system is not used to relieve sudden breathing problems and does not replace a rescue inhaler.
The inhaler enables patients to track how frequently they are using their inhalers. This may help inform conversations with their doctors about treatment adherence and correct technique.
The inhaler contains built-in sensors that detect when it is being used and measure inspiratory flow rates. The data are then sent to a companion mobile app, which allows patients to review their data over time and share it with their healthcare providers.
Employee Spotlight (1)
Expert Insights (3)
Government Relations (21)
Policy Update (2)
Technology and Innovation (19)